Shanghai Henlius Biotech Future Growth

Future criteria checks 4/6

Shanghai Henlius Biotech is forecast to grow earnings and revenue by 15.8% and 9.9% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be 28.3% in 3 years.

Key information

15.8%

Earnings growth rate

13.7%

EPS growth rate

Biotechs earnings growth	35.0%
Revenue growth rate	9.9%
Future return on equity	28.3%
Analyst coverage	Good
Last updated	02 May 2024

Recent future growth updates

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Recent updates

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22

Earnings and Revenue Growth Forecasts

SEHK:2696 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	7,411	887	853	1,349	4
12/31/2025	6,451	710	357	1,248	6
12/31/2024	5,875	594	374	1,343	6
12/31/2023	5,395	546	36	1,048	N/A
9/30/2023	5,008	55	-192	945	N/A
6/30/2023	4,426	-203	185	1,417	N/A
3/31/2023	3,820	-449	-99	1,199	N/A
12/31/2022	3,215	-695	-384	982	N/A
9/30/2022	2,659	-638	-683	655	N/A
6/30/2022	2,338	-842	-1,267	-11	N/A
3/31/2022	2,010	-913	-1,154	40	N/A
12/31/2021	1,682	-984	-1,041	90	N/A
9/30/2021	1,397	-962	-1,329	-28	N/A
6/30/2021	1,111	-939	-1,617	-146	N/A
3/31/2021	849	-966	-1,870	-378	N/A
12/31/2020	588	-994	-2,122	-610	N/A
9/30/2020	386	-1,000	-1,851	-657	N/A
6/30/2020	184	-1,007	-1,580	-704	N/A
3/31/2020	145	-941	-1,638	-608	N/A
12/31/2019	91	-875	-1,364	-443	N/A
9/30/2019	58	-747	-1,327	-318	N/A
6/30/2019	24	-619	-1,289	-194	N/A
3/31/2019	8	-591	-925	-124	N/A
12/31/2018	7	-494	-788	-52	N/A
12/31/2017	34	-271	-606	-134	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2696's forecast earnings growth (15.8% per year) is above the savings rate (2.2%).

Earnings vs Market: 2696's earnings (15.8% per year) are forecast to grow faster than the Hong Kong market (12% per year).

High Growth Earnings: 2696's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2696's revenue (9.9% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).

High Growth Revenue: 2696's revenue (9.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2696's Return on Equity is forecast to be high in 3 years time (28.3%)

Shanghai Henlius Biotech Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Forecast breakeven date moved forward to 2023

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Recent updates

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02

Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd)

Shanghai Henlius Biotech, Inc. Announces the Phase 1b/2 Clinical Trial of Hlx07

Shanghai Henlius Biotech, Inc. Announces Dosage of First Subject in Phase 1 Clinical Study of HLX15 (Recombinant Anti-CD38 Humanmonoclonal Antibody Injection) in Healthy Chinese Male Subjects

Shanghai Henlius Biotech, Inc. Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

Shanghai Henlius Biotech Announces the First Patient Dosage in the United States of America in an International Multi-Centre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in A Phase 1 Clinical Trialof Hlx60 (Recombinant Humanized Anti-Garp Monoclonalantibody Injection) in Combination with Hansizhuang(Serplulimab Injection) for the Treatment of Advanced Ormetastatic Solid Tumors in Australia

Shanghai Henlius Biotech, Inc. Doses First Patient in A Phase 1 Clinical Trial of anti-TIGIT Fc Fusion Protein HLX53 for the Treatment of advanced/Metastatic Solid Tumours or Lymphomasin Mainland China

Shanghai Henlius Biotech, Inc. Announces the First Patient Was Dosed in NCT05468489

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Bridging Study Comparing Hansizhuang (Serplulimab Injection) Versus Atezolizumab

Shanghai Henlius Biotech, Inc. Announces Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy Approved to Commence A Phase 3 Clinical Trial

Less than half of directors are independent

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1b/2 Clinical Trial of HLX208

Shanghai Henlius Biotech, Inc. Receives Investigational New Drug Approval from China's National Medical Products Administration for A Phase 2 Clinical Trial of AC101

Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication Ofhansizhuang (Serplulimab Injection) in Combination Withchemotherapy for the First-Line Treatment of Squamousnon-Small Cell Lung Cancer Has Been Approved by Thenational Medical Products Administration

Shanghai Henlius Biotech, Inc. announces the Phase 2 Clinical Trial of Hlx22 in Combination Withhansizhuang (Serplulimab Injection) and Thestandard Therapy As the First-Line Treatment for Locally Advancedor Metastatic Gastric Cancer (Gc) Has Been Approvedby the National Medical Products Admin

Shanghai Henlius Biotech, Inc. Announces Approval of Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy to Commence A Phase 3 Clinical Trial for the Treatment of Limited-Stage Small Cell Lung Cancer in Australia

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Hlx60 for the Treatment of Solidtumours and Lymphomas Was Approved by the Nationalmedical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Hlx60 for the Treatment of Solidtumours and Lymphomas Was Approved by the Nationalmedical Products Administration

Shanghai Henlius Biotech, Inc. Announces Results of Phase 1 Clinical Trial Demonstrating Good Safety and Tolerability for HLX22 (Anti-Human Epidermal Growth Factor Receptor-2 (HER2) Humanised Monoclonal Antibody Injection) for the Treatment of HER2 Overexpressing Advanced Solid Tumours

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces the New Drug Application for New Indication of Hansizhuang Accepted by the Center for Drug Evaluation of the National Medical Products Administration

Forecast to breakeven in 2024

Shanghai Henlius Biotech, Inc. Announces Executive Changes